Shaw Richard J, Mackay Daniel, Pell Jill P, Padmanabhan Sandosh, Bailey David S, Smith Daniel J
Institute of Health and Wellbeing, University of Glasgow, Glasgow, UK.
Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK.
Psychol Med. 2021 May;51(7):1183-1191. doi: 10.1017/S0033291719004094. Epub 2020 Jan 24.
Recent work suggests that antihypertensive medications may be useful as repurposed treatments for mood disorders. Using large-scale linked healthcare data we investigated whether certain classes of antihypertensive, such as angiotensin antagonists (AAs) and calcium channel blockers, were associated with reduced risk of new-onset major depressive disorder (MDD) or bipolar disorder (BD).
Two cohorts of patients treated with antihypertensives were identified from Scottish prescribing (2009-2016) and hospital admission (1981-2016) records. Eligibility for cohort membership was determined by a receipt of a minimum of four prescriptions for antihypertensives within a 12-month window. One treatment cohort (n = 538 730) included patients with no previous history of mood disorder, whereas the other (n = 262 278) included those who did. Both cohorts were matched by age, sex and area deprivation to untreated comparators. Associations between antihypertensive treatment and new-onset MDD or bipolar episodes were investigated using Cox regression.
For patients without a history of mood disorder, antihypertensives were associated with increased risk of new-onset MDD. For AA monotherapy, the hazard ratio (HR) for new-onset MDD was 1.17 (95% CI 1.04-1.31). Beta blockers' association was stronger (HR 2.68; 95% CI 2.45-2.92), possibly indicating pre-existing anxiety. Some classes of antihypertensive were associated with protection against BD, particularly AAs (HR 0.46; 95% CI 0.30-0.70). For patients with a past history of mood disorders, all classes of antihypertensives were associated with increased risk of future episodes of MDD.
There was no evidence that antihypertensive medications prevented new episodes of MDD but AAs may represent a novel treatment avenue for BD.
近期研究表明,抗高血压药物可重新用于治疗情绪障碍。我们利用大规模的关联医疗数据,调查了某些类型的抗高血压药物,如血管紧张素拮抗剂(AA)和钙通道阻滞剂,是否与新发重度抑郁症(MDD)或双相情感障碍(BD)风险降低有关。
从苏格兰的处方记录(2009 - 2016年)和医院入院记录(1981 - 2016年)中确定了两组接受抗高血压治疗的患者。队列成员资格的确定标准是在12个月内至少接受过4次抗高血压药物处方。一个治疗队列(n = 538730)包括既往无情绪障碍病史的患者,另一个队列(n = 262278)包括有情绪障碍病史的患者。两个队列均按年龄、性别和地区贫困程度与未接受治疗的对照者进行匹配。使用Cox回归研究抗高血压治疗与新发MDD或双相情感发作之间的关联。
对于无情绪障碍病史的患者,抗高血压药物与新发MDD风险增加有关。对于AA单药治疗,新发MDD的风险比(HR)为1.17(95%CI 1.04 - 1.31)。β受体阻滞剂的关联更强(HR 2.68;95%CI 2.45 - 2.92),这可能表明存在先前的焦虑。某些类型的抗高血压药物与预防BD有关,特别是AA(HR 0.46;95%CI 0.30 - 0.70)。对于有情绪障碍病史的患者,所有类型的抗高血压药物都与未来MDD发作风险增加有关。
没有证据表明抗高血压药物可预防MDD的新发作,但AA可能是BD的一种新治疗途径。